P3 Health Partners Inc. (NASDAQ:PIII) Short Interest Down 50.4% in June

by · The Markets Daily

P3 Health Partners Inc. (NASDAQ:PIII – Get Free Report) was the target of a large decline in short interest during the month of June. As of June 15th, there was short interest totaling 68,522 shares, a decline of 50.4% from the May 31st total of 138,133 shares. Based on an average trading volume of 103,356 shares, the days-to-cover ratio is currently 0.7 days. Currently, 1.1% of the shares of the company are sold short.

Hedge Funds Weigh In On P3 Health Partners

A hedge fund recently bought a new stake in P3 Health Partners stock. Lido Advisors LLC acquired a new stake in shares of P3 Health Partners Inc. (NASDAQ:PIII – Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 10,748 shares of the company’s stock, valued at approximately $33,000. Lido Advisors LLC owned 0.15% of P3 Health Partners as of its most recent filing with the Securities & Exchange Commission. 7.75% of the stock is owned by hedge funds and other institutional investors.

P3 Health Partners Trading Up 2.7%

Shares of P3 Health Partners stock traded up $0.30 on Thursday, reaching $11.37. 67,299 shares of the company were exchanged, compared to its average volume of 682,367. P3 Health Partners has a fifty-two week low of $1.52 and a fifty-two week high of $16.89. The firm has a market capitalization of $82.32 million, a price-to-earnings ratio of -0.29 and a beta of 1.62. The stock has a fifty day moving average price of $9.14 and a 200-day moving average price of $5.06.

P3 Health Partners (NASDAQ:PIII – Get Free Report) last announced its earnings results on Thursday, May 14th. The company reported $0.32 EPS for the quarter, topping the consensus estimate of ($4.85) by $5.17. The firm had revenue of $386.39 million during the quarter, compared to analyst estimates of $391.45 million.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on PIII. Weiss Ratings upgraded P3 Health Partners from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, May 28th. TD Cowen restated a “hold” rating and set a $14.00 price objective (up from $3.00) on shares of P3 Health Partners in a research report on Friday, May 22nd. UBS Group set a $14.00 target price on P3 Health Partners in a research report on Friday, May 15th. Finally, Lake Street Capital reiterated a “buy” rating and issued a $14.00 target price (up from $4.00) on shares of P3 Health Partners in a research note on Friday, May 15th. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, P3 Health Partners currently has a consensus rating of “Hold” and a consensus target price of $14.00.

View Our Latest Report on PIII

About P3 Health Partners

(Get Free Report)

P3 Health Partners is a healthcare technology and services company that delivers data-driven solutions to support health plans in improving quality measures, risk adjustment accuracy and operational efficiency. The company’s platform integrates advanced analytics, reporting capabilities and workflow automation to help clients optimize performance across value-based care programs and regulatory requirements.

The company’s core offerings include quality measurement and reporting for HEDIS, STAR and other performance frameworks, risk adjustment coding and audit services, and population health analytics.

Featured Stories